Genmab — December 2017
-
Det må vel betragtes som positivt at de øger omkostningerne til Tisotumab Vedotin. Det tyder på en tiltro til produktet. Ikke at tiltroen er ny, men det cementerer den i høj grad.
-
-
-
Kan Genmab finansiere sin pipeline med royalties er det et stærkt tegn for salget af Darzalex. Med en snit-behandlingstid på 30 mdr må flere finanshuse skifte ud i deres ligning, som dikterer deres kurstarget i forhold indregningen af Darzelex salg.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind